Americafirst Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Americafirst Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$700K	Buy	+1,565	New	+$745K	0.95%	22

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Americafirst Capital Management's REGN Position: Q3 2017 in Review

Americafirst Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2017: 1,565 shares worth $700K. The stake represents 0.95% of the portfolio and ranks #22 among its holdings.

605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

Americafirst Capital Management held 1,565 shares of Regeneron Pharmaceuticals worth $700K as of Q3 2017.
Regeneron Pharmaceuticals was a new Americafirst Capital Management position in Q3 2017.
Regeneron Pharmaceuticals made up 0.95% of Americafirst Capital Management's portfolio in Q3 2017, its #22 holding.
605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Americafirst Capital Management's 13F filing for Q3 2017, filed 16 Nov 2017.